ACADIA Pharmaceuticals Inc. (ACAD)

ACADIA Pharmaceuticals' stock price has experienced significant movement, increasing by 49.61% from January 13, 2025, to January 9, 2026, and delivering a 55.86% change over the past year, with a 52-week range between $13.40 and $28.35. Key events impacting the stock include strong financial results reported in Q3 2025, the FDA approval of DAYBUE STIX, analyst ratings and price target adjustments, and business and pipeline updates provided at the J.P. Morgan Healthcare Conference.

Based on the available information, there is no explicit mention of demand seasonality for ACADIA Pharmaceuticals' products and services. The company has reported consistent year-over-year increases in net product sales for both NUPLAZID and DAYBUE, indicating a stable or growing demand rather than seasonal fluctuations. The company's focus on chronic neurological and rare diseases suggests a continuous need for its treatments, which typically do not exhibit strong seasonal patterns.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases, operating within the biotechnology and medical research sector, with a focus on neurology. Its major commercial products include NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis (PDP) and DAYBUE (trofinetide) for Rett syndrome. The company also has a pipeline of product candidates and research programs addressing unmet needs in CNS disorders and rare diseases.

ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California, U.S. While its commercial products, NUPLAZID and DAYBUE, are primarily commercialized in the United States, the company has a broader international presence through subsidiaries and offices in Denmark, Germany, Italy, the Netherlands, and the United Kingdom. ACADIA is also advancing its pipeline globally, with a Phase 3 trial for trofinetide in Rett syndrome initiated in Japan.

ACADIA Pharmaceuticals maintains a positive brand reputation, driven by its commitment to addressing unmet medical needs in neurological and rare diseases. The FDA approvals of NUPLAZID and DAYBUE, the advancement of its pipeline, and the company's leadership and strategic vision have contributed to its reputation. There is no readily available information indicating any significant negative events that have affected ACADIA Pharmaceuticals' brand reputation in the past year.

ACADIA Pharmaceuticals Inc. has a significant institutional ownership presence, with institutional investors holding approximately 88.93% of the company's shares. Major institutional owners include Baker Bros. Advisors Lp, BlackRock, Inc., Vanguard Group Inc, State Street Corp, iShares Core S&P Small-Cap ETF (IJR), Rtw Investments, Lp, and Geode Capital Management, Llc. Insiders account for a notable portion of ownership, with Baker Bros Advisors LP also being a significant insider shareholder. Individual investors hold a smaller percentage, around 0.64%.